Literature DB >> 17786322

The receptor tyrosine kinase Tie1 is expressed and activated in epithelial tumour cell lines.

Kathryn A Rees1, Harprit Singh, Nicholas P J Brindle.   

Abstract

The receptor tyrosine kinase Tie1 is expressed primarily in vascular endothelial cells. The receptor has also been detected in epithelial tumours in breast, thyroid and gastric cancers and in tumour cell lines where it appears as a 45 kDa truncated receptor fragment. In this study, we show that in addition to truncated Tie1, breast and colon tumour cell lines express a full-length Tie1 holoreceptor. In contrast to the situation in endothelial cells, Tie1 truncation is not activated by phorbol esters and generation of truncated Tie1 does not occur via a metalloprotease-inhibitor sensitive mechanism. Examination of the phosphorylation status of Tie1 revealed both the holoreceptor and truncated receptor to be constitutively activated in MCF-7 cells. These data indicate that Tie1 expressed in epithelial tumour cell lines is present in holoreceptor and truncated forms, and in MCF-7 cells both forms are constitutively phosphorylated and competent to signal. Our findings suggest therefore that anti-angiogenic strategies targeting the angiopoietin/Tie system in tumour microvasculature could also have additional direct effects on the tumour epithelial cells within those tumours in which there is also extravascular expression of the Tie1 receptor tyrosine kinase.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17786322

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  10 in total

Review 1.  Long non-coding RNAs and cancer: a new frontier of translational research?

Authors:  R Spizzo; M I Almeida; A Colombatti; G A Calin
Journal:  Oncogene       Date:  2012-01-23       Impact factor: 9.867

2.  Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

Authors:  Josep Tabernero; Heinz-Josef Lenz; Salvatore Siena; Alberto Sobrero; Alfredo Falcone; Marc Ychou; Yves Humblet; Olivier Bouché; Laurent Mineur; Carlo Barone; Antoine Adenis; Takayuki Yoshino; Richard M Goldberg; Daniel J Sargent; Andrea Wagner; Dirk Laurent; Michael Teufel; Michael Jeffers; Axel Grothey; Eric Van Cutsem
Journal:  Lancet Oncol       Date:  2015-07-13       Impact factor: 41.316

Review 3.  Tie-1: A potential target for anti-angiogenesis therapy.

Authors:  Ping Yang; Na Chen; Jing-Hui Jia; Xue-Jiao Gao; Shi-Han Li; Jing Cai; Zehua Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-10-22

4.  Heterogeneity of vascular and progenitor cell compartments in tumours from MMTV-PyVmT transgenic mice during mammary cancer progression.

Authors:  Mackenzie J Smith; Robert W Berger; Kanwal Minhas; Roger A Moorehead; Brenda L Coomber
Journal:  Int J Exp Pathol       Date:  2010-11-08       Impact factor: 1.925

Review 5.  Angiogenesis and autosomal dominant polycystic kidney disease.

Authors:  Jennifer L Huang; Adrian S Woolf; David A Long
Journal:  Pediatr Nephrol       Date:  2012-09-19       Impact factor: 3.714

Review 6.  Proteolytic cleavage, trafficking, and functions of nuclear receptor tyrosine kinases.

Authors:  Mei-Kuang Chen; Mien-Chie Hung
Journal:  FEBS J       Date:  2015-07-04       Impact factor: 5.542

7.  Evaluation of expression and function of vascular endothelial growth factor receptor 2, platelet derived growth factor receptors-alpha and -beta, KIT, and RET in canine apocrine gland anal sac adenocarcinoma and thyroid carcinoma.

Authors:  Bridget K Urie; Duncan S Russell; William C Kisseberth; Cheryl A London
Journal:  BMC Vet Res       Date:  2012-05-25       Impact factor: 2.741

8.  Colorectal adenoma to carcinoma progression is accompanied by changes in gene expression associated with ageing, chromosomal instability, and fatty acid metabolism.

Authors:  Beatriz Carvalho; Anke H Sillars-Hardebol; Cindy Postma; Sandra Mongera; Jochim Terhaar Sive Droste; Askar Obulkasim; Mark van de Wiel; Wim van Criekinge; Bauke Ylstra; Remond J A Fijneman; Gerrit A Meijer
Journal:  Cell Oncol (Dordr)       Date:  2012-01-26       Impact factor: 6.730

9.  Potential of Tyrosine Kinase Receptor TIE-1 as Novel Therapeutic Target in High-PI3K-Expressing Ovarian Cancer.

Authors:  Xuewei Zhang; Masumi Ishibashi; Kazuyuki Kitatani; Shogo Shigeta; Hideki Tokunaga; Masafumi Toyoshima; Muneaki Shimada; Nobuo Yaegashi
Journal:  Cancers (Basel)       Date:  2020-06-26       Impact factor: 6.639

Review 10.  Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease.

Authors:  T Makinde; D K Agrawal
Journal:  J Cell Mol Med       Date:  2008-02-04       Impact factor: 5.310

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.